Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Genomics, Proteomics & Bioinformatics|February 24, 2018
Human Gut Microbiota and Gastrointestinal CancerChangting Meng, Chunmei Bai, Thomas D Brown, et al.
Translational Oncology|April 8, 2014
Adjuvant Chemotherapy with Docetaxel, Cisplatin, and Continuous-Infusion 5-Fluorouracil for Gastric Cancer: A Phase II StudyChangting Meng, Hongyan Yin, Zhao Sun, et al.
Experimental Hematology|February 25, 2021
Single-cell analysis of erythropoiesis in Rpl11 haploinsufficient mice reveals insight into the pathogenesis of Diamond-Blackfan anemiaRaymond T Doty, Xiaowei Yan, Changting Meng, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|September 27, 2015
Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumorsYuejuan Cheng, Zhao Sun, Chunmei Bai, et al.
Translational Oncology|June 24, 2014
Gefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Case-Control StudyNan-Jie Zhao, Zhao Sun, Yuzhou Wang, et al.
BMC Cancer|August 28, 2014
MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinomaZhao Sun, Changting Meng, Shihua Wang, et al.
Blood Advances|June 23, 2023
The transcriptomic landscape of normal and ineffective erythropoiesis at single-cell resolutionRaymond T Doty, Christopher G Lausted, Adam D Munday, et al.
BMC Pulmonary Medicine|September 7, 2021
Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progressionYingyi Wang, Na Zhou, Rui Zhu, et al.
Oncology Reports|December 29, 2015
Genetic analysis in a patient with nine primary malignant neoplasms: a rare case of Li-Fraumeni syndromeXiaoyuan Li, Juan Kang, Qi Pan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2024
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck CancerPaul L Swiecicki, Emrullah Yilmaz, Ari Joseph Rosenberg, et al.
Pageof 2